http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104013626-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 |
| filingDate | 2014-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104013626-B |
| titleOfInvention | Pyridine-piperazine compounds is preparing the application in anti-HIV-1 virus drugs |
| abstract | The invention discloses pyridine-piperazine compounds and preparing the application in anti-HIV-1 virus drugs, does is the general formula of this compound n in formula:n base is positioned at 1 or No. 2 position; R, R are independently the chain alkylene of C1 ~ C5 or the cyclic hydrocarbon radical of C4 ~ C6.Inventor utilizes the interaction of Vif-APOBEC3G, confirm the compound of above-mentioned general formula, particularly 1-cyclopenta-4-[(pyridine-2-base) carbonyl] piperazine can suppress the activity of Vif protein degradation A3G, causes the expression of screening system Green fluorescin to go up.By the primary CD4+ people T lymphocyte and H9, SupT 1 CD4+ such as grade the infection experiment carrying out wild type HIV-1 virus in T lymphocyte series confirms that it has good antivirus action further.For further antiviral drugs researches and develops the strong theoretical basis and practical basis provided, there is important research and development value and development significance. |
| priorityDate | 2014-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 57.